x
Breaking News
0

Gilead Sciences Inc (GILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Gilead's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
75.62 +1.28    +1.72%
19:39:41 GMT - Real-time CFD Data. Currency in USD ( Disclaimer )
Type: Equity
Market: United States
ISIN: US3755581036 
CUSIP: 375558103
  • Volume: 6,154,480
  • Bid/Ask: 75.62 / 75.64
  • Day's Range: 74.10 - 75.73
Start Trading
Gilead 75.62 +1.28 +1.72%

GILD Overview

 
Information about the Gilead Sciences Inc Stock. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close74.34
Day's Range74.1 - 75.73
Revenue27.48B
Open75.08
52 wk Range63.76 - 86.27
EPS8.79
Volume6,154,480
Market Cap97.08B
Dividend (Yield)2.03 (2.8%)
Average Vol. (3m)9,546,583
P/E Ratio8.46
Beta1.15
1-Year Change - 1.81%
Shares Outstanding1,307,000,000
Next Earnings DateFeb 05, 2018
What is your sentiment on Gilead?
or
Vote to see community's results!

Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Buy Buy Buy Buy Buy
Technical Indicators Strong Buy Strong Buy Strong Buy Strong Buy BUY
Summary Strong Buy Strong Buy Strong Buy Strong Buy Buy

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Completed Patterns
Deliberation Bearish 1D 3 Dec 12, 2017
Doji Star Bearish 1D 3 Dec 12, 2017
Upside Gap Three Methods 5H 7 Dec 12, 2017 07:00AM
Engulfing Bearish 1D 9 Dec 04, 2017
Bullish doji Star 5H 12 Dec 07, 2017 12:00PM

Gilead Sciences Inc News & Analysis

News


Gilead Sciences Inc Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 75.62 75.62 75.64 6,154,480 +1.72% USD 19:39:41  
  Mexico 1,456.70 1,400.29 1,456.70 52 +2.95% MXN 19:17:13  
  Switzerland 76.100 58.000 104.400 0 0.00% CHF 13/12  
  Switzerland 74.850 0.000 0.000 0 0.00% USD 11/12  
  Frankfurt 63.86 64.28 64.33 2,324 +0.48% EUR 15:45:00  
  Berlin 63.130 64.250 64.340 0 -2.20% EUR 07:08:00  
  TradeGate 64.37 64.33 64.42 5,436 +2.57% EUR 18:47:00  
  Munich 63.300 0.000 0.000 113 -0.71% EUR 09:31:00  
  Xetra 63.9950 63.6400 63.9100 4,860 +0.59% EUR 16:35:00  
  Stuttgart 63.882 64.330 64.420 150 +1.56% EUR 16:18:00  
  Vienna 63.925 0.000 0.000 0 +0.22% EUR 16:32:00  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  LongFin A 23.80 26.43 7.86 +18.40 +340.76% 13.01M 19:39:28  
  Amazon.com 1,178.63 1,182.75 1,169.33 +4.37 +0.37% 2.88M 19:39:34  
  Tesla 339.46 342.93 335.80 +1.57 +0.46% 4.63M 19:39:44  
  NVIDIA 190.48 192.38 185.67 +4.01 +2.15% 11.30M 19:39:41  
  Riot Blockchain 28.8101 29.4900 26.7900 +3.8301 +15.33% 10.64M 19:39:37  
  AMD 10.280 10.320 10.020 +0.150 +1.48% 25.11M 19:39:35  
  Apple 173.46 173.68 172.46 +1.24 +0.72% 23.29M 19:39:41  
  Teva ADR 18.41 18.70 17.50 +1.11 +6.45% 53.77M 19:39:39  
  Digital Power 4.805 5.070 4.680 -0.195 -3.91% 6.92M 19:39:30  
  Alibaba 172.71 173.04 170.00 +0.96 +0.56% 21.17M 19:39:42  

Gilead Sciences Inc Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

9000

Equity Type

ORD

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
U.S. Commodity Futures Trading Commission (United States) Start Trading
U.S. Commodity Futures Trading Commission (United States) $250 Start Trading
National Futures Association (United States), U.S. Commodity Futures Trading Commission (United States), The Financial Conduct Authority (United Kingdom), Australian Securities and Investments Commission (Australia), Financial Industry Regulatory Authority (United States), Investment Industry Regulatory Organization of Canada (Canada), Securities and Exchange Board of India (India), Securities and Exchange Commission (United States), The Securities and Futures Commission (Hong Kong), Securities Investor Protection Corporation (United States) $10000 Start Trading

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

 
Are you sure you want to delete this chart?
 
Write your thoughts about Gilead Sciences Inc
 
Replace the attached chart with a new chart ?
Post
Post also to:
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

Latest GILD Comments

Sal Monella
Sal Monella Nov 16, 2017 11:51PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Typical WALL STREET fraud & theft! Company beats earnings estimates for 4 consecutive quarters TOP to BOTTOM & they crash the stock by 15% in following 3-4 weeks, after KITE acquisition & positive FDA Nescarta data. Even that greedy ***of a fraudster Jim Cramer was still telling people to sell in the low 70s. Please God. Next time, put Cramer in that bike path for the next lone wolf to run over.
Reply
0 0
Episcopolian OptionTrader
Episcopolian1 Oct 02, 2017 5:11PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$GILD The NASH Phase 2 data release iis now delayed until end-of-the-yea, possibly 1st qtr of 2018. Not good! but very good sign for $ICPT
Reply
0 0
Episcopolian OptionTrader
Episcopolian1 Oct 03, 2017 2:10PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sell $GILD and buy $ICPT
Reply
0 0
Episcopolian OptionTrader
Episcopolian1 Sep 28, 2017 2:08PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Floor chatter about Phase 2 NASH has failed!
Reply
0 0
Show more comments
 
Are you sure you want to delete this chart?
 
 
Replace the attached chart with a new chart ?
Post 1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email